Background Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins. It is uncertain whether triglycerides predict risk after ACS on a background of statin treatment.
Objectives This study examined the relationship of fasting triglyceride levels to outcomes after ACS in patients treated with statins.
Methods Long-term and short-term relationships of triglycerides to risk after ACS were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively. Analysis of dal-OUTCOMES included 15,817 patients (97% statin-treated) randomly assigned 4 to 12 weeks after ACS to treatment with dalcetrapib (a cholesteryl ester transfer protein inhibitor) or placebo and followed for a median 31 months. Analysis of MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS and followed for 16 weeks. Fasting triglycerides at initial random assignment were related to risk of coronary heart disease death, nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass index.
Results Fasting triglyceride levels were associated with both long-term and short-term risk after ACS. In dal-OUTCOMES, long-term risk increased across quintiles of baseline triglycerides (p < 0.001). The hazard ratio in the highest/lowest quintile (>175/≤80 mg/dl) was 1.61 (95% confidence interval: 1.34-1.94). There was no interaction of triglycerides and treatment assignment on the primary outcome. In the atorvastatin group of MIRACL, short-term risk increased across tertiles of baseline triglycerides (p = 0.03), with a hazard ratio of 1.50 (95% confidence interval: 1.05 to 2.15) in highest/lowest tertiles (>195/≤135 mg/dl). The relationship of triglycerides to risk was independent of low-density lipoprotein cholesterol in both studies.
Conclusions Among patients with ACS treated effectively with statins, fasting triglycerides predict long-term and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy.
Trigs a target for therapy ! So should we expect another drug from Big Pharma in the near future and we know what happened in their abysmal attempt to raise HDL with drugs, maybe they should view the success of LC in significantly reducing trigs and rasing HDL safely without the need for potentially risky drug interventions.
the first sentence in the first paragraph seems to be evidence of experimental bias:
"... statins, which reduce ATHEROGENIC triglyceride-rich lipoproteins". I suppose if you start with that sort of assumption its all downhill on the way to the cashier's office.
However since trig levels depend very strongly on carb intake maybe big pharma could devise a drug which renders dietary carbs inert, call it 'Abstinence' perhaps or 'Satisfaction' or something catchy like that?
You find great information. I am improving my knowledge through reading your blog thank you :)
Post a Comment